<DOC>
	<DOCNO>NCT00003405</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Biological therapy use different way stimulate immune system stop cancer cell grow . Combining one chemotherapy drug biological therapy may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy , isotretinoin , interferon alfa treat patient acute myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Biological Therapy Treating Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I. Assess efficacy high dose cytarabine mitoxantrone amifostine induction therapy patient previously untreated standard risk acute myelogenous leukemia ( AML ) . II . Assess effect amifostine biology AML cell vivo patient . III . Determine whether relationship cytokine production remission induction therapy treatment outcome . OUTLINE : Prior treatment , patient undergo bone marrow aspirate biopsy . On day -3 , patient receive idoxuridine IV 60 minute follow immediately bone marrow aspirate biopsy . Patients receive amifostine IV 5-7 minute day . Prior chemotherapy day 1 , patient receive broxuridine IV 60 minute immediately follow bone marrow aspirate biopsy . Chemotherapy day 1 consist amifostine follow cytarabine IV 3 hour repeat every 12 hour mitoxantrone IV 1 hour immediately second infusion cytarabine . This course repeat day 5 another bone marrow biopsy aspirate . Starting day 6 , patient receive amifostine 3 time week day 28 beyond . Patients respond treatment continue receive three course consolidation therapy . Consolidation course 1 3 consist cytarabine continuous IV day 1-7 idarubicin IV 30 minute day 1 , 2 , 3 . Consolidation course 2 consist cytarabine IV 75 minute repeat every 12 hour 4 day . Twenty-four hour course consolidation therapy , patient receive isotretinoin orally every day interferon alfa subcutaneously every day . Isotretinoin interferon alfa therapy stop 4 day prior day 1 next course consolidation therapy . Following recovery course 3 consolidation therapy , patient continue receive isotretinoin/interferon alfa relapse . Patients complete remission 3 course consolidation therapy receive isotretinoin/interferon alfa 3 year . Patients follow every 3 month first year , every 6 month next 2 year . PROJECTED ACCRUAL : There 40-45 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Bromodeoxyuridine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Idoxuridine</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm previously untreated acute myelogenous leukemia ( AML ) FAB M1 , M2 , M4 , M5 , M6 , M7 No AML secondary chemotherapy , radiation therapy , toxic agent No history myelodysplastic syndrome If possible , patient enrol protocol RUSHCYL9003 PATIENT CHARACTERISTICS : Age : 70 Performance status : 03 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL great 3.0 mg/dL allow 50 % reduction drug dose Renal : Creatinine le 3.0 mg/dL Cardiovascular : No overt congestive heart failure No uncontrollable ventricular arrhythmia No uncontrollable hypertension If cardiac ejection fraction le 45 % predict , echocardiogram cardiac consult must obtain ascertain cardiac tolerance anthracycline therapy Neurological : No cerebellar dysfunction Other : Fever , infection , complication disease allow Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : At least 2 week since prior interferon At least 2 week since prior hematopoietic growth factor ( include erythropoietin ) Chemotherapy : At least 2 week since prior chemotherapy Endocrine therapy : At least 2 week since prior steroid Radiotherapy : Not specify Surgery : Not specify Other : At least 2 week since prior retinoids</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>childhood acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>childhood acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>childhood acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>childhood acute monoblastic leukemia ( M5a )</keyword>
	<keyword>childhood acute monocytic leukemia ( M5b )</keyword>
	<keyword>childhood acute erythroleukemia ( M6 )</keyword>
	<keyword>childhood acute megakaryocytic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
</DOC>